Eli Lilly and Company News Releases https://investor.lilly.com/ Eli Lilly and Company News Releases en Lilly Presents Positive Results for Taltz® (ixekizumab) vs. Humira® (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis at the European Congress of Rheumatology https://investor.lilly.com/news-releases/news-release-details/lilly-presents-positive-results-taltzr-ixekizumab-vs-humirar INDIANAPOLIS , June 14, 2019 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) announced today that the company will present positive findings from the Phase 3b/4 SPIRIT-Head-to-Head (H2H) study in patients with active psoriatic arthritis (PsA) as a late-breaking abstract at the European Congress Fri, 14 Jun 2019 06:45:00 -0400 Eli Lilly and Company News Releases 41451 Lilly to Present 5-Year Sustained Efficacy and Safety Results for Taltz® (ixekizumab) in Patients with Plaque Psoriasis at the World Congress of Dermatology https://investor.lilly.com/news-releases/news-release-details/lilly-present-5-year-sustained-efficacy-and-safety-results INDIANAPOLIS , June 11, 2019 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) announced today the company will present positive, five-year Phase 3 data for Taltz ® (ixekizumab). Patients with moderate- to severe plaque psoriasis who continued to receive Taltz maintained high levels of skin Tue, 11 Jun 2019 03:00:00 -0400 Eli Lilly and Company News Releases 41446 Detailed findings from CAROLINA® outcome trial support long-term cardiovascular safety profile of Tradjenta® https://investor.lilly.com/news-releases/news-release-details/detailed-findings-carolinar-outcome-trial-support-long-term - CAROLINA® demonstrated no increased cardiovascular risk for Tradjenta® (linagliptin) versus glimepiride in the only active-comparator cardiovascular outcome trial for a dipeptidyl peptidase-4 (DPP-4) inhibitor - Adults with diabetes treated with Tradjenta experienced fewer events of hypoglycemia Mon, 10 Jun 2019 21:30:00 -0400 Eli Lilly and Company News Releases 41441 New analysis shows cardiorenal risk reductions of Jardiance® are consistent in adults with type 2 diabetes, cardiovascular disease and kidney disease without overt proteinuria https://investor.lilly.com/news-releases/news-release-details/new-analysis-shows-cardiorenal-risk-reductions-jardiancer-are - Findings from an EMPA-REG OUTCOME® post-hoc analysis of adults with chronic kidney disease without overt proteinuria presented at American Diabetes Association's 79th Scientific Sessions® RIDGEFIELD , Conn. and INDIANAPOLIS , June 10, 2019 /PRNewswire/ -- A new post-hoc analysis of data from the Mon, 10 Jun 2019 13:00:00 -0400 Eli Lilly and Company News Releases 41436 Trulicity® (dulaglutide) significantly reduced major cardiovascular events for broad range of people with type 2 diabetes https://investor.lilly.com/news-releases/news-release-details/trulicityr-dulaglutide-significantly-reduced-major REWIND data showed a consistent effect in people with and without established cardiovascular disease INDIANAPOLIS , June 9, 2019 /PRNewswire/ -- Detailed results from REWIND, the Trulicity ® (dulaglutide) cardiovascular outcome trial, showed a significant 12 percent reduction in major Sun, 09 Jun 2019 19:30:00 -0400 Eli Lilly and Company News Releases 41426 Lilly's ultra rapid lispro provided similar A1C reductions compared to Humalog® (insulin lispro), with superior post-meal blood glucose reductions https://investor.lilly.com/news-releases/news-release-details/lillys-ultra-rapid-lispro-provided-similar-a1c-reductions Pivotal phase 3 data in people with type 1 and type 2 diabetes presented at the American Diabetes Association's® 79th Scientific Sessions® INDIANAPOLIS , June 9, 2019 /PRNewswire/ -- Two phase 3 studies show that Eli Lilly and Company's (NYSE: LLY) ultra rapid lispro Sun, 09 Jun 2019 11:30:00 -0400 Eli Lilly and Company News Releases 41421 Lilly's tirzepatide demonstrates benefits in data presented at the American Diabetes Association's® 79ᵗʰ Scientific Sessions® https://investor.lilly.com/news-releases/news-release-details/lillys-tirzepatide-demonstrates-benefits-data-presented-american INDIANAPOLIS , June 8, 2019 /PRNewswire/ -- Results from several studies of  Eli Lilly and Company's (NYSE: LLY) investigational dual GIP and GLP-1 receptor agonist (RA), tirzepatide, reinforce its potential in lowering A1C and body weight in people with type 2 diabetes. Sat, 08 Jun 2019 20:30:00 -0400 Eli Lilly and Company News Releases 41416 Lilly to Present New Data and Commitment to Patient-Centered Solutions at the Annual European Congress of Rheumatology https://investor.lilly.com/news-releases/news-release-details/lilly-present-new-data-and-commitment-patient-centered-solutions - Thirty abstracts will reflect investigations into the treatment of a broad range of rheumatic diseases - INDIANAPOLIS , June 6, 2019 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) will present data for Taltz ® (ixekizumab) and Olumiant ® (baricitinib) at the Annual European Congress of Thu, 06 Jun 2019 06:45:00 -0400 Eli Lilly and Company News Releases 41411 Lilly to Showcase Scientific Innovation within Dermatology Portfolio at 24th World Congress of Dermatology https://investor.lilly.com/news-releases/news-release-details/lilly-showcase-scientific-innovation-within-dermatology - Eighteen abstracts will reveal new insights for the management of moderate-to-severe plaque psoriasis and psoriatic arthritis, as well as the potential treatment of moderate-to-severe atopic dermatitis and alopecia areata - INDIANAPOLIS , June 5, 2019 /PRNewswire/ --  Eli Lilly and Company (NYSE: Wed, 05 Jun 2019 06:45:00 -0400 Eli Lilly and Company News Releases 41401 FDA Approves Emgality® (galcanezumab-gnlm) as the First and Only Medication for the Treatment of Episodic Cluster Headache that Reduces the Frequency of Attacks https://investor.lilly.com/news-releases/news-release-details/fda-approves-emgalityr-galcanezumab-gnlm-first-and-only -With this approval, Emgality is the only calcitonin gene-related peptide (CGRP) antibody indicated for the preventive treatment of migraine and the treatment of episodic cluster headache[1] INDIANAPOLIS , June 4, 2019 /PRNewswire/ --   Eli Lilly and Company (NYSE: LLY) announced today that the Tue, 04 Jun 2019 21:01:00 -0400 Eli Lilly and Company News Releases 41396 U.S. FDA Accepts New Drug Application for Triple Combination Tablet for Adults with Type 2 Diabetes https://investor.lilly.com/news-releases/news-release-details/us-fda-accepts-new-drug-application-triple-combination-tablet RIDGEFIELD , Conn. and INDIANAPOLIS , June 4, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration ( FDA ) has accepted the New Drug Application (NDA) for the investigational fixed-dose combination tablet of empagliflozin, linagliptin and metformin extended release (XR) for the treatment of Tue, 04 Jun 2019 07:30:00 -0400 Eli Lilly and Company News Releases 41386 Hurricane Season is Almost Here. Are You Ready? https://investor.lilly.com/news-releases/news-release-details/hurricane-season-almost-here-are-you-ready Lilly, Healthcare Ready and Direct Relief Helping People Prepare for Disasters, Ensure Medicines are Available INDIANAPOLIS , May 31, 2019 /PRNewswire/ -- The 2019 Atlantic hurricane season begins June 1 . With natural disasters and extreme weather on the rise, it's critical to be prepared and Fri, 31 May 2019 07:00:00 -0400 Eli Lilly and Company News Releases 41381 Lilly to Participate in Goldman Sachs Global Healthcare Conference https://investor.lilly.com/news-releases/news-release-details/lilly-participate-goldman-sachs-global-healthcare-conference-3 INDIANAPOLIS , May 30, 2019 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) will participate in the Goldman Sachs 40 th Annual Global Healthcare Conference on Wednesday, June 12, 2019 . Joshua Smiley , senior vice president and Lilly's chief financial officer, will participate in a fireside chat Thu, 30 May 2019 16:15:00 -0400 Eli Lilly and Company News Releases 41376 Lilly Announces Webcast to Discuss ADA Presentations and Diabetes Portfolio https://investor.lilly.com/news-releases/news-release-details/lilly-announces-webcast-discuss-ada-presentations-and-diabetes INDIANAPOLIS , May 29, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will conduct a webcast on Monday, June 10, 2019 to discuss the company's diabetes portfolio and its presentations at the American Diabetes Association's 79th Scientific Sessions in San Francisco, California . Wed, 29 May 2019 16:15:00 -0400 Eli Lilly and Company News Releases 41371 Lilly Announces Licensing Agreement for Non-Opioid Pain Asset from Centrexion Therapeutics https://investor.lilly.com/news-releases/news-release-details/lilly-announces-licensing-agreement-non-opioid-pain-asset INDIANAPOLIS , May 28, 2019 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) today announced a license agreement to acquire the exclusive worldwide rights for CNTX-0290 from Centrexion Therapeutics Corporation , a company focused on developing non-opioid, non-addictive therapeutics for the Tue, 28 May 2019 07:54:00 -0400 Eli Lilly and Company News Releases 41361 Lilly's Lower-Priced Insulin Now Available https://investor.lilly.com/news-releases/news-release-details/lillys-lower-priced-insulin-now-available List price of Lilly's Insulin Lispro Injection 50 percent less than branded Humalog INDIANAPOLIS , May 22, 2019 /PRNewswire/ --  Eli Lilly and Company's (NYSE: LLY) Insulin Lispro Injection is now available for order in pharmacies for people who use Lilly's rapid-acting insulin and need a Wed, 22 May 2019 06:30:00 -0400 Eli Lilly and Company News Releases 41336 Lilly's Mirikizumab Met Primary Endpoint and Key Secondary Endpoints in Phase 2 Study, Including Reductions of Gastrointestinal Lesions https://investor.lilly.com/news-releases/news-release-details/lillys-mirikizumab-met-primary-endpoint-and-key-secondary The safety and efficacy data from the induction period of the Phase 2 trial encourage Lilly to initiate a Phase 3 trial for mirikizumab for the treatment of Crohn's disease later this year INDIANAPOLIS , May 21, 2019 /PRNewswire/ -- In an oral presentation from the Digestive Disease Week medical Tue, 21 May 2019 13:15:00 -0400 Eli Lilly and Company News Releases 41331 Lilly to Participate in UBS Global Healthcare Conference https://investor.lilly.com/news-releases/news-release-details/lilly-participate-ubs-global-healthcare-conference-1 INDIANAPOLIS , May 16, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will attend the UBS Global Healthcare Conference on Tuesday, May 21, 2019 . Christi Shaw , president of Lilly Bio-Medicines, will participate in a fireside chat at 9:30 a.m., Eastern Time. Thu, 16 May 2019 16:30:00 -0400 Eli Lilly and Company News Releases 41316 Data Presentations at ASCO 2019 Highlight Lilly's Targeted Approach to Developing Treatments for Patients Living with Cancer https://investor.lilly.com/news-releases/news-release-details/data-presentations-asco-2019-highlight-lillys-targeted-approach Lung cancer highlights to include the first presentation of RELAY results and additional findings from KEYNOTE-189 Lilly to share data from Phase 3 ANNOUNCE trial in people with advanced soft tissue sarcoma INDIANAPOLIS , May 15, 2019 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) today Wed, 15 May 2019 17:00:00 -0400 Eli Lilly and Company News Releases 41311 Lilly to Participate in Bank of America Merrill Lynch Health Care Conference https://investor.lilly.com/news-releases/news-release-details/lilly-participate-bank-america-merrill-lynch-health-care-1 INDIANAPOLIS , May 15, 2019 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) will participate in the Bank of America Merrill Lynch 2019 Health Care Conference on Wednesday, May 15, 2019 . Enrique Conterno , senior vice president of Lilly and president of Lilly Diabetes and Lilly USA , will Wed, 15 May 2019 06:30:00 -0400 Eli Lilly and Company News Releases 41306 Lilly's CYRAMZA® (ramucirumab) Becomes First FDA-Approved Biomarker-Driven Therapy in Patients with Hepatocellular Carcinoma https://investor.lilly.com/news-releases/news-release-details/lillys-cyramzar-ramucirumab-becomes-first-fda-approved-biomarker This new indication - the fifth FDA approval for CYRAMZA in an advanced or metastatic cancer - is for the second-line treatment of patients with hepatocellular carcinoma (HCC) who are AFP-High (AFP ≥400 ng/mL) Approximately forty percent of all patients with advanced HCC are AFP-High and are a Mon, 13 May 2019 06:45:00 -0400 Eli Lilly and Company News Releases 41301 AAN 2019: Two New Analyses of Lasmiditan Phase 3 Studies Measured Onset of Effect and the Effect of Lasmiditan in Patients with Prior Triptan Experience https://investor.lilly.com/news-releases/news-release-details/aan-2019-two-new-analyses-lasmiditan-phase-3-studies-measured - The lasmiditan Phase 3 program encompassed more than 4,000 patients and 20,000 migraine attacks[1,2,3] INDIANAPOLIS , May 8, 2019 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) today announced new data and post-hoc analyses for lasmiditan, an investigational, oral, first-in-class molecule for Wed, 08 May 2019 06:45:00 -0400 Eli Lilly and Company News Releases 41286 Lilly Declares Second-Quarter 2019 Dividend https://investor.lilly.com/news-releases/news-release-details/lilly-declares-second-quarter-2019-dividend INDIANAPOLIS , May 6, 2019 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2019 of $0.645 per share on outstanding common stock. The dividend is payable June 10, 2019 , to shareholders of record at the close of business Mon, 06 May 2019 14:16:00 -0400 Eli Lilly and Company News Releases 41266 AAN 2019: Pooled Analyses of Two Emgality® (galcanezumab-gnlm) Phase 3 Studies Show Reduction in Monthly Migraine Headache Days in Low- and High-Frequency Episodic Migraine Subgroups https://investor.lilly.com/news-releases/news-release-details/aan-2019-pooled-analyses-two-emgalityr-galcanezumab-gnlm-phase-3 INDIANAPOLIS , May 6, 2019 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) today announced the upcoming presentation of results from pooled subgroup analyses of efficacy data from the Phase 3 EVOLVE-1 and EVOLVE-2 studies. These analyses demonstrate a reduction in monthly migraine headache days Mon, 06 May 2019 06:45:00 -0400 Eli Lilly and Company News Releases 41261 Lilly to Present New Data at AAN 2019 on Emgality® (galcanezumab-gnlm) and Lasmiditan Reinforcing Breadth of Headache Disorders Portfolio https://investor.lilly.com/news-releases/news-release-details/lilly-present-new-data-aan-2019-emgalityr-galcanezumab-gnlm-and - 19 abstracts to be presented, including Phase 3, eight-week data on Emgality for the preventive treatment of episodic cluster headache in adults, featured in a plenary presentation - First-time presentation of lasmiditan clinical data on the onset of response for the acute treatment of migraine Thu, 02 May 2019 06:45:00 -0400 Eli Lilly and Company News Releases 41231 Lilly Reports Solid First-Quarter 2019 Financial Results, Updates 2019 Guidance to Reflect Disposition of Elanco Animal Health https://investor.lilly.com/news-releases/news-release-details/lilly-reports-solid-first-quarter-2019-financial-results-updates - Revenue in the first quarter of 2019 grew 3 percent, driven by 7 percent volume growth. Key growth products launched since 2014, including Trulicity, Taltz, Verzenio, Basaglar, Olumiant, Jardiance, Cyramza and Emgality represented approximately 39 percent of revenue and delivered strong volume Tue, 30 Apr 2019 06:25:00 -0400 Eli Lilly and Company News Releases 41221 U.S. Court of Appeals Rules in Favor of Lilly in Alimta Vitamin Regimen Patent Lawsuit https://investor.lilly.com/news-releases/news-release-details/us-court-appeals-rules-favor-lilly-alimta-vitamin-regimen-patent INDIANAPOLIS , April 26, 2019 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Court of Appeals for the Federal Circuit has ruled in the company's favor regarding patentability of the vitamin regimen for Alimta® (pemetrexed for injection). Fri, 26 Apr 2019 11:28:00 -0400 Eli Lilly and Company News Releases 41201 Lilly to Establish an Access Program for Patients as it Prepares to Withdraw Lartruvo from the Global Market https://investor.lilly.com/news-releases/news-release-details/lilly-establish-access-program-patients-it-prepares-withdraw Lilly is working to ensure current patients access to Lartruvo with limited interruption after it is withdrawn from the market INDIANAPOLIS , April 25, 2019 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) today announced that the company has been working to facilitate the withdrawal of Lartruvo® Thu, 25 Apr 2019 06:45:00 -0400 Eli Lilly and Company News Releases 41196 Lilly Announces Sale of Legacy Antibiotics Brands and Manufacturing Facility in China https://investor.lilly.com/news-releases/news-release-details/lilly-announces-sale-legacy-antibiotics-brands-and-manufacturing INDIANAPOLIS , April 22, 2019 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) today announced that it has entered into an agreement to sell the rights in China for two legacy Lilly antibiotic medicines, Ceclor ® and Vancocin ® , as well as a manufacturing facility in Suzhou, China that produces Mon, 22 Apr 2019 22:05:00 -0400 Eli Lilly and Company News Releases 41186 Lilly Announces Positive Top-Line Results for COAST-X, a 52-Week Placebo-Controlled Study of Taltz® (ixekizumab) in Patients with Non-Radiographic Axial Spondyloarthritis https://investor.lilly.com/news-releases/news-release-details/lilly-announces-positive-top-line-results-coast-x-52-week INDIANAPOLIS , April 22, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Taltz ®  (ixekizumab) met the primary and all major secondary endpoints in COAST-X, a Phase 3 study evaluating the safety and efficacy of Taltz for the treatment of non-radiographic axial Mon, 22 Apr 2019 06:45:00 -0400 Eli Lilly and Company News Releases 41171